Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019
August 21, 2019 at 11:51 am EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was CNY 689.240 million compared to CNY 982.291 million a year ago. Operating income was CNY 70.266 million compared to CNY 104.096 million a year ago. Net income was CNY 63.034 million compared to CNY 66.914 million a year ago. Basic earnings per share from continuing operations was CNY 0.0716 compared to CNY 0.076 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.
HUNAN JINGFENG PHARMACEUTICAL CO.,LTD. 
